81 related articles for article (PubMed ID: 17637761)
1. Efficacy of maximal androgen blockade versus castration alone in the treatment of advanced prostate cancer: a retrospective clinical experience from a Chinese medical centre.
Chen XQ; Huang Y; Li X; Zhang P; Huang R; Xia J; Chen N; Wei Q; Zhu YC; Yang YR; Zeng H
Asian J Androl; 2010 Sep; 12(5):718-27. PubMed ID: 20694018
[TBL] [Abstract][Full Text] [Related]
2. A feasibility study evaluating the functional diffusion map as a predictive imaging biomarker for detection of treatment response in a patient with metastatic prostate cancer to the bone.
Lee KC; Bradley DA; Hussain M; Meyer CR; Chenevert TL; Jacobson JA; Johnson TD; Galban CJ; Rehemtulla A; Pienta KJ; Ross BD
Neoplasia; 2007 Dec; 9(12):1003-11. PubMed ID: 18084607
[TBL] [Abstract][Full Text] [Related]
3. Patient Priorities Concerning Treatment Decisions for Advanced Neuroendocrine Tumors Identified by Discrete Choice Experiments.
Anaka M; Chan D; Pattison S; Thawer A; Franco B; Moody L; Jackson C; Segelov E; Singh S
Oncologist; 2024 Mar; 29(3):227-234. PubMed ID: 38007397
[TBL] [Abstract][Full Text] [Related]
4. Discrete-Choice Experiment to Understand the Preferences of Patients with Hormone-Sensitive Prostate Cancer in the USA, Canada, and the UK.
Gonzalez JM; Ganguli A; Morgans AK; Tombal BF; Hotte SJ; Suzuki H; Bhadauria H; Oh M; Scales CD; Wallace MJ; Yang JC; George DJ
Patient; 2023 Nov; 16(6):607-623. PubMed ID: 37566214
[TBL] [Abstract][Full Text] [Related]
5. Patient and General Population Preferences Regarding the Benefits and Harms of Treatment for Metastatic Prostate Cancer: A Discrete Choice Experiment.
Menges D; Piatti MC; Omlin A; Cathomas R; Benamran D; Fischer S; Iselin C; Küng M; Lorch A; Prause L; Rothermundt C; O'Meara Stern A; Zihler D; Lippuner M; Braun J; Cerny T; Puhan MA
Eur Urol Open Sci; 2023 May; 51():26-38. PubMed ID: 37187724
[TBL] [Abstract][Full Text] [Related]
6. Eliciting men's preferences for decision-making relative to treatments of localized prostate cancer with a good or moderate prognosis.
Lejeune C; Bourredjem A; Binquet C; Cussenot O; Boudrant G; Papillon F; Bruyère F; Haillot O; Koutlidis N; Bassard S; Fournier G; Valeri A; Moreau JL; Pierfitte B; Moulin M; Berchi C; Cormier L
World J Urol; 2023 Jun; 41(6):1541-1549. PubMed ID: 37173454
[TBL] [Abstract][Full Text] [Related]
7. Patient Preference Studies for Advanced Prostate Cancer Treatment Along the Medical Product Life Cycle: Systematic Literature Review.
Menges D; Piatti MC; Cerny T; Puhan MA
Patient Prefer Adherence; 2022; 16():1539-1557. PubMed ID: 35789822
[TBL] [Abstract][Full Text] [Related]
8. Physicochemical Profile of Antiandrogen Drug Bicalutamide: Solubility, Distribution, Permeability.
Volkova TV; Simonova OR; Perlovich GL
Pharmaceutics; 2022 Mar; 14(3):. PubMed ID: 35336047
[TBL] [Abstract][Full Text] [Related]
9. A Systematic Review of Discrete Choice Experiments in Oncology Treatments.
Collacott H; Soekhai V; Thomas C; Brooks A; Brookes E; Lo R; Mulnick S; Heidenreich S
Patient; 2021 Nov; 14(6):775-790. PubMed ID: 33950476
[TBL] [Abstract][Full Text] [Related]
10. Patient and caregiver benefit-risk preferences for nonmetastatic castration-resistant prostate cancer treatment.
Srinivas S; Mohamed AF; Appukkuttan S; Botteman M; Ng X; Joshi N; Tsai JH; Fang J; Waldeck AR; Simmons SJ
Cancer Med; 2020 Sep; 9(18):6586-6596. PubMed ID: 32725755
[TBL] [Abstract][Full Text] [Related]
11. Physician preferences for non-metastatic castration-resistant prostate cancer treatment.
Srinivas S; Mohamed AF; Appukkuttan S; Botteman M; Ng X; Joshi N; Horodniceanu E; Waldeck AR; Simmons SJ
BMC Urol; 2020 Jun; 20(1):73. PubMed ID: 32571276
[TBL] [Abstract][Full Text] [Related]
12. Patient Preferences and Urologist Judgments on Prostate Cancer Therapy in Japan.
Nakayama M; Kobayashi H; Okazaki M; Imanaka K; Yoshizawa K; Mahlich J
Am J Mens Health; 2018 Jul; 12(4):1094-1101. PubMed ID: 29774804
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of patient preference and willingness to pay for attributes of maintenance medication for chronic obstructive pulmonary disease (COPD).
Kawata AK; Kleinman L; Harding G; Ramachandran S
Patient; 2014; 7(4):413-26. PubMed ID: 24890711
[TBL] [Abstract][Full Text] [Related]
14. Risk as an attribute in discrete choice experiments: a systematic review of the literature.
Harrison M; Rigby D; Vass C; Flynn T; Louviere J; Payne K
Patient; 2014; 7(2):151-70. PubMed ID: 24566923
[TBL] [Abstract][Full Text] [Related]
15. Eliciting patient preferences for hormonal therapy options in the treatment of metastatic prostate cancer.
Lloyd A; Penson D; Dewilde S; Kleinman L
Prostate Cancer Prostatic Dis; 2008; 11(2):153-9. PubMed ID: 17637761
[TBL] [Abstract][Full Text] [Related]
16. Prostate-cancer-specific survival and clinical progression-free survival in men with prostate cancer treated intermittently with testosterone-inactivating pharmaceuticals.
Scholz M; Lam R; Strum S; Jennrich R; Johnson H; Trilling T
Urology; 2007 Sep; 70(3):506-10. PubMed ID: 17905106
[TBL] [Abstract][Full Text] [Related]
17. Bicalutamide.
Prescrire Int; 2007 Apr; 16(88):67. PubMed ID: 17458049
[TBL] [Abstract][Full Text] [Related]
18. [Antiandrogen in prostate cancer].
Maeda O; Usami M
Nihon Rinsho; 2002 Dec; 60 Suppl 11():188-92. PubMed ID: 12599569
[No Abstract] [Full Text] [Related]
19. [Usefulness and positioning of MAB therapy for prostate cancer].
Akaza H; Chodak GW; Hirao Y
Gan To Kagaku Ryoho; 2005 Oct; 32(10):1507-20. PubMed ID: 16227758
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
